Healthcare / BiotechnologyTaipei Exchange
$19.80
-0.20 (-1.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-49.7M · quality 59.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$696M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-18.6%
↓Gross Margin
78.0%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+19.5%
FCF CAGR
—
FCF margin
-143.2%
FCF / Net income
0.85x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $27.0M · net income $-45.8M · FCF $-38.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $27.0M | $27.0M | $23.3M | $20.2M | $15.9M |
| Net Income | $-45.8M | $-45.8M | $-54.3M | $-38.2M | $-188.7M |
| EBITDA | $-28.0M | $-28.0M | $-35.8M | $-17.7M | $-146.3M |
| EPS | — | — | -1.54 | -1.19 | -6.14 |
| Gross Margin | 78.0% | 78.0% | 55.2% | 2.6% | 57.3% |
| Operating Margin | -174.5% | -174.5% | -247.5% | -225.3% | -1207.5% |
| Net Margin | -169.2% | -169.2% | -232.6% | -189.0% | -1189.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.03 | 0.01 | 0.29 |
| Current Ratio | 11.41 | 11.41 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-38.7M | $-38.7M | $-49.7M | $-83.1M | $-210.6M |
| Returns | |||||
| ROE | -18.6% | -18.6% | -18.4% | -10.7% | -75.8% |
| Valuation | |||||
| P/B | 2.83 | 2.83 | 4.12 | 3.44 | 11.60 |
| Growth & Yield | |||||
| Revenue Growth | 15.9% | 15.9% | 15.6% | 27.4% | — |
| EPS Growth | — | — | -29.4% | 80.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-33.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.54 → n/d
Residual
-33.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.